1,031 reports of this reaction
2.8% of all BUSULFAN reports
#7 most reported adverse reaction
VENOOCCLUSIVE LIVER DISEASE is the #7 most commonly reported adverse reaction for BUSULFAN, manufactured by Otsuka America Pharmaceutical, Inc.. There are 1,031 FDA adverse event reports linking BUSULFAN to VENOOCCLUSIVE LIVER DISEASE. This represents approximately 2.8% of all 36,413 adverse event reports for this drug.
Patients taking BUSULFAN who experience venoocclusive liver disease should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
VENOOCCLUSIVE LIVER DISEASE is a less commonly reported adverse event for BUSULFAN, but still significant enough to appear in the safety profile.
In addition to venoocclusive liver disease, the following adverse reactions have been reported for BUSULFAN:
The following drugs have also been linked to venoocclusive liver disease in FDA adverse event reports:
VENOOCCLUSIVE LIVER DISEASE has been reported as an adverse event in 1,031 FDA reports for BUSULFAN. This does not prove causation, but indicates an association observed in post-market surveillance data.
VENOOCCLUSIVE LIVER DISEASE accounts for approximately 2.8% of all adverse event reports for BUSULFAN, making it a notable side effect.
If you experience venoocclusive liver disease while taking BUSULFAN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.